SMC^® Amyloid Beta 42 High Sensitivity Immunoassay Kit

Amyloid Beta 1-42 (Aβ1-42) is a peptide derived from the proteolytic cleavage of the amyloid precursor protein (APP), a transmembrane protein implicated in neuronal development and function. Aβ1-42 is particularly notable for its propensity to aggregate into toxic oligomers and fibrils, which are key components of amyloid plaques found in the brains of individuals with neurodegenerative diseases, especially Alzheimer′s disease (AD).

Aβ1-42 plays a critical role in the pathogenesis of Alzheimer′s disease. Elevated levels of Aβ1-42 are associated with the development of amyloid plaques, which can disrupt neuronal function, trigger neuroinflammation, and lead to neuronal cell death. The presence of Aβ1-42 in the cerebrospinal fluid (CSF) is often inversely correlated with cognitive decline, making it a valuable biomarker for early diagnosis and monitoring of Alzheimer′s disease. Understanding the function and implications of Aβ1-42 is essential for developing targeted therapies aimed at reducing amyloid burden and mitigating its detrimental effects on brain health in neurodegenerative conditions.

Neuroscience/Neurological Disorders/Signaling

Although Amyloid Beta 42 was detectable in mouse and rat samples, the assay has not been verified for these species.

96 well assay

Neuroscience

Neurological Disorders

Neurodegenerative Diseases

Alzheimer′s Disease

FEMTOQUEST is a trademark of Merck KGaA, Darmstadt, Germany

SMC is a registered trademark of Singulex

SMCxPRO is a registered trademark of Merck KGaA, Darmstadt, Germany

Our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.